Frequency of antibiotic application drives rapid evolutionary adaptation of Escherichia coli persistence

Article metrics

Abstract

The evolution of antibiotic resistance is a major threat to society and has been predicted to lead to 10 million casualties annually by 20501. Further aggravating the problem, multidrug tolerance in bacteria not only relies on the build-up of resistance mutations, but also on some cells epigenetically switching to a non–growing antibiotic-tolerant ‘persister’ state26. Yet, despite its importance, we know little of how persistence evolves in the face of antibiotic treatment7. Our evolution experiments in Escherichia coli demonstrate that extremely high levels of multidrug tolerance (20–100%) are achieved by single point mutations in one of several genes and readily emerge under conditions approximating clinical, once-daily dosing schemes. In contrast, reversion to low persistence in the absence of antibiotic treatment is relatively slow and only partially effective. Moreover, and in support of previous mathematical models810, we show that bacterial persistence quickly adapts to drug treatment frequency and that the observed rates of switching to the persister state can be understood in the context of ‘bet-hedging’ theory. We conclude that persistence is a major component of the evolutionary response to antibiotics that urgently needs to be considered in both diagnostic testing and treatment design in the battle against multidrug tolerance.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Frequent antibiotic exposure leads to the fast emergence of high survival levels.
Figure 2: Single mutations in evolved clones cause multidrug tolerance, not by increased antibiotic resistance but by increased persistence.
Figure 3: Costs and benefits of persistence under contrasting levels of antibiotic exposure.
Figure 4: Persister levels quickly adapt in response to the frequency of antibiotic treatment.

References

  1. 1

    Review on Antimicrobial Resistance. Tackling a Crisis for the Health and Wealth of Nations (2015); http://amr-review.org/sites/default/files/Report-52.15.pdf

  2. 2

    Balaban, N. Q., Merrin, J., Chait, R., Kowalik, L. & Leibler, S. Bacterial persistence as a phenotypic switch. Science 305, 1622–1625 (2004).

  3. 3

    Lewis, K. Persister cells. Annu. Rev. Microbiol. 64, 357–372 (2010).

  4. 4

    Fauvart, M., De Groote, V. N. & Michiels, J. Role of persister cells in chronic infections: clinical relevance and perspectives on anti-persister therapies. J. Med. Microbiol. 60, 699–709 (2011).

  5. 5

    Maisonneuve, E. & Gerdes, K. Molecular mechanisms underlying bacterial persisters. Cell 157, 539–548 (2014).

  6. 6

    Verstraeten, N. et al. Obg and membrane depolarization are part of a microbial bet-hedging strategy that leads to antibiotic tolerance. Mol. Cell 59, 9–21 (2015).

  7. 7

    Balaban, N. Q., Gerdes, K., Lewis, K. & McKinney, J. D. A problem of persistence: still more questions than answers? Nature Rev. Microbiol. 11, 587–591 (2013).

  8. 8

    Kussell, E., Kishony, R., Balaban, N. Q. & Leibler, S. Bacterial persistence: a model of survival in changing environments. Genetics 169, 1807–1814 (2005).

  9. 9

    Gardner, A., West, S. A. & Griffin, A. S. Is bacterial persistence a social trait? PLoS ONE 2, e752 (2007).

  10. 10

    Patra, P. & Klumpp, S. Population dynamics of bacterial persistence. PLoS ONE 8, e62814 (2013).

  11. 11

    Balázsi, G., Van Oudenaarden, A. & Collins, J. J. Cellular decision making and biological noise: from microbes to mammals. Cell 144, 910–925 (2011).

  12. 12

    Veening, J.-W., Smits, W. K. & Kuipers, O. P. Bistability, epigenetics, and bet-hedging in bacteria. Annu. Rev. Microbiol. 62, 193–210 (2008).

  13. 13

    Kint, C. I., Verstraeten, N., Fauvart, M. & Michiels, J. New-found fundamentals of bacterial persistence. Trends Microbiol. 20, 577–585 (2012).

  14. 14

    Stepanyan, K. et al. Fitness trade-offs explain low levels of persister cells in the opportunistic pathogen Pseudomonas aeruginosa. Mol. Ecol. 24, 1572–1583 (2015).

  15. 15

    Mulcahy, L. R., Burns, J. L., Lory, S. & Lewis, K. Emergence of Pseudomonas aeruginosa strains producing high levels of persister cells in patients with cystic fibrosis. J. Bacteriol. 192, 6191–6199 (2010).

  16. 16

    Fridman, O., Goldberg, A., Ronin, I., Shoresh, N. & Balaban, N. Q. Optimization of lag time underlies antibiotic tolerance in evolved bacterial populations. Nature 513, 418–421 (2014).

  17. 17

    Lee, H. H., Molla, M. N., Cantor, C. R. & Collins, J. J. Bacterial charity work leads to population-wide resistance. Nature 467, 82–85 (2010).

  18. 18

    Allison, K. R., Brynildsen, M. P. & Collins, J. J. Metabolite-enabled eradication of bacterial persisters by aminoglycosides. Nature 473, 216–220 (2011).

  19. 19

    Wakamoto, Y. et al. Dynamic persistence of antibiotic-stressed mycobacteria. Science 339, 91–95 (2013).

  20. 20

    Orman, M. A. & Brynildsen, M. P. Dormancy is not necessary or sufficient for bacterial persistence. Antimicrob. Agents Chemother. 57, 3230–3239 (2013).

  21. 21

    Acar, M., Mettetal, J. T. & van Oudenaarden, A. Stochastic switching as a survival strategy in fluctuating environments. Nature Genet. 40, 471–475 (2008).

  22. 22

    Philippi, T. & Seger, J. Hedging one's evolutionary bets, revisited. Trends Ecol. Evol. 4, 41–44 (1989).

  23. 23

    Baskin, C. C. & Baskin, J. M. Seeds: ecology, biogeography, and evolution of dormancy and germination (Elsevier, 2014).

  24. 24

    Beaumont, H. J. E., Gallie, J., Kost, C., Ferguson, G. C. & Rainey, P. B. Experimental evolution of bet hedging. Nature 462, 90–93 (2009).

  25. 25

    Kussell, E. & Leibler, S. Phenotypic diversity, population growth, and information in fluctuating environments. Science 309, 2075–2078 (2005).

  26. 26

    McKenzie, C. Antibiotic dosing in critical illness. J. Antimicrob. Chemother. 66, ii25–ii31 (2011).

  27. 27

    ABC Project Team Ascertaining Barriers for Compliance: Policies for Safe, Effective and Cost-effective use of Medicines in Europe (2012); http://abcproject.eu/img/ABCFinal.pdf

  28. 28

    Oz, T. et al. Strength of selection pressure is an important parameter contributing to the complexity of antibiotic resistance evolution. Mol. Biol. Evol. 31, 2387–2401 (2014).

  29. 29

    Andersson, D. I. & Hughes, D. Antibiotic resistance and its cost: is it possible to reverse resistance? Nature Rev. Microbiol. 8, 260–271 (2010).

  30. 30

    Cohen, N. R., Lobritz, M. A. & Collins, J. J. Microbial persistence and the road to drug resistance. Cell Host Microbe 13, 632–642 (2013).

  31. 31

    Yu, J., Xiao, J., Ren, X., Lao, K. & Xie, X. S. Probing gene expression in live cells, one protein molecule at a time. Science 311, 1600–1603 (2006).

  32. 32

    Cherepanov, P. P. & Wackernagel, W. Gene disruption in Escherichia coli: TcR and KmR cassettes with the option of Flp-catalyzed excision of the antibiotic-resistance determinant. Gene 158, 9–14 (1995).

  33. 33

    Fux, C. A., Costerton, J. W., Stewart, P. S. & Stoodley, P. Survival strategies of infectious biofilms. Trends Microbiol. 13, 34–40 (2005).

  34. 34

    Eng, R. H. K., Padberg, F. T., Smith, S. M., Tan, E. N. & Cherubin, C. E. Bactericidal effects of antibiotics on slowly growing and nongrowing bacteria. Antimicrob. Agents Chemother. 35, 1824–1828 (1991).

  35. 35

    Wu, M.-L., Tan, J. & Dick, T. Eagle effect in non-replicating persister Mycobacteria. Antimicrob. Agents Chemother. 59, 7786–7789 (2015).

  36. 36

    Gocke, E. Mechanism of quinolone mutagenicity in bacteria. Mutat. Res. 248, 135–143 (1991).

  37. 37

    Rodríguez-Rojas, A., Rodríguez-Beltrán, J., Couce, A. & Blázquez, J. Antibiotics and antibiotic resistance: A bitter fight against evolution. Int. J. Med. Microbiol. 303, 293–297 (2013).

  38. 38

    Lázár, V. et al. Genome-wide analysis captures the determinants of the antibiotic cross-resistance interaction network. Nature Commun. 5, 4352 (2014).

  39. 39

    Ruiz, J. Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection. J. Antimicrob. Chemother. 51, 1109–1117 (2003).

  40. 40

    Kim, S., Lieberman, T. D. & Kishony, R. Alternating antibiotic treatments constrain evolutionary paths to multidrug resistance. Proc. Natl Acad. Sci. 111, 14494–14499 (2014).

  41. 41

    Wiser, M. J., Ribeck, N. & Lenski, R. E. Long-term dynamics of adaptation in asexual populations. Science 1364, 1364–1367 (2013).

  42. 42

    Wiegand, I., Hilpert, K. & Hancock, R. E. W. Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nature Protoc. 3, 163–175 (2008).

  43. 43

    Liebens, V. et al. Identification and characterization of an anti-pseudomonal dichlorocarbazol derivative displaying anti-biofilm activity. Bioorg. Med. Chem. Lett. 24, 5404–5408 (2014).

  44. 44

    Thierauf, A., Perez, G. & Maloy, A. S. Generalized transduction. Methods Mol. Biol. 501, 267–286 (2009).

  45. 45

    Baba, T. et al. Construction of Escherichia coli K-12 in-frame, single-gene knockout mutants: the Keio collection. Mol. Syst. Biol. 2, 2006.0008 (2006).

  46. 46

    Otto, S. P. & Day, T. A Biologist's Guide to Mathematical Modeling in Ecology and Evolution (Princeton University Press, 2007).

  47. 47

    Helaine, S. et al. Dynamics of intracellular bacterial replication at the single cell level. Proc. Natl Acad. Sci. 107, 3746–3751 (2010).

  48. 48

    Francois, K. et al. Modelling the individual cell lag phase. Isolating single cells: protocol development . Lett. Appl. Microbiol. 37, 26–30 (2003).

Download references

Acknowledgements

B.V.D.B. is a Research Foundation - Flanders (FWO)-fellow and J.E.M. is a fellow of the Agency for Innovation by Science and Technology (IWT). The research was supported by the KU Leuven Research Council (PF/10/010; PF/10/07; IDO/09/010; IDO/13/008; CREA/13/019; DBOF/12/035; DBOF/14/049), Interuniversity Attraction Poles–Belgian Science Policy Office (IAP-BELSPO) (IAP P7/28), ERC (241426), Human Frontier Science Program (HFSP) (RGP0050/2013), FWO (G047112N, KAN2014 1.5.222.14), Flanders Institute for Biotechnology(VIB) and the European Molecular Biology organisation (EMBO). We thank S. Xie for providing the ancestor strains and E. Toprak and S. Diggle for their comments on this manuscript.

Author information

B.V.D.B. designed and performed the experiments, analysed the data and wrote the manuscript. J.E.M. helped in performing the experiments and analysing the data and edited the manuscript. T.W. made the evolutionary model, helped in analysing the data and edited the manuscript. E.M.W. helped in analysing the evolutionary model. P.V.B. and D.K. helped in performing the experiments. L.D.M. and K.J.V. edited the manuscript. N.V., M.F. and J.M. designed the experiments and edited the manuscript. J.E.M. and T.W. contributed equally. M.F. and J.M. contributed equally as senior authors.

Correspondence to Jan Michiels.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary information

Supplementary Figures 1-8, Tables 1 and 2, Methods and References. (PDF 1311 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Van den Bergh, B., Michiels, J., Wenseleers, T. et al. Frequency of antibiotic application drives rapid evolutionary adaptation of Escherichia coli persistence. Nat Microbiol 1, 16020 (2016) doi:10.1038/nmicrobiol.2016.20

Download citation

Further reading